Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ACTU
ACTU logo

ACTU Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Actuate Therapeutics Inc (ACTU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.350
1 Day change
0.15%
52 Week Range
11.990
Analysis Updated At
2026/05/07
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

ACTU is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 right now. The stock has short-term momentum, but there is no proprietary buy signal, no SwingMax entry, no recent news catalyst, and the latest quarter shows worsening profitability with negative EPS and net income. The Wall Street view is still positive on balance because H.C. Wainwright kept a Buy rating, but the target was cut sharply to $15 from $20, which signals reduced conviction. Based on the data, the best direct call is to hold and wait rather than buy now.

Technical Analysis

ACTU is showing a short-term bullish setup but not a clean high-conviction entry. The MACD histogram is positive and expanding, which supports upward momentum. However, RSI_6 at 75.634 suggests the stock is already extended, and the moving averages are converging, which points to a less decisive trend. Price closed at 3.37, above pivot 2.963 and above R1 3.322, indicating strength, but it is still below the next resistance at R2 3.544. Overall, the chart is constructive in the near term, but not ideal for a beginner long-term entry at current levels.

Positive Catalysts

  • ["MACD histogram is positive and expanding, showing improving momentum.", "Price closed above the pivot and first resistance, indicating near-term strength.", "H.C. Wainwright still maintains a Buy rating on the stock.", "Post-market change remained slightly positive at 0.90%, showing some follow-through strength."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "AI Stock Picker: no signal on given stock today.", "SwingMax: no signal on given stock recently.", "Analyst price target was cut from $20 to $15, which is a negative revision.", "Latest quarter financials weakened: net income fell to -4.55M and EPS declined to -0.19.", "Insiders and hedge funds are neutral, with no meaningful buying trend.", "No recent congress trading data available.", "RSI is elevated, suggesting the stock may be stretched after the move."]

Financial Performance

In 2025/Q4, ACTU reported revenue of 0, flat year over year, while net income worsened to -4,553,953, down 29.35% YoY. EPS also dropped to -0.19, down 38.71% YoY. Gross margin was unchanged at 0. The latest quarter season indicates the business is still operating at a loss and does not yet show improving fundamental momentum.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wall Street remains cautiously positive but less optimistic than before. On 2026-04-13, H.C. Wainwright lowered its price target on ACTU to $15 from $20 while keeping a Buy rating after the Q4 report. That means analysts still see upside, but the reduced target shows a weaker near-term outlook. Pros: Buy rating remains intact and target still sits well above the current price. Cons: the target cut is significant and reflects softer expectations, and there is no broad analyst momentum or recent news support.

Wall Street analysts forecast ACTU stock price to rise
2 Analyst Rating
Wall Street analysts forecast ACTU stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.340
sliders
Low
20
Averages
22.5
High
25
Current: 3.340
sliders
Low
20
Averages
22.5
High
25
H.C. Wainwright
Swayampakula Ramakanth
Buy
downgrade
$20 -> $15
AI Analysis
2026-04-13
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$20 -> $15
AI Analysis
2026-04-13
downgrade
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Actuate Therapeutics to $15 from $20 and keeps a Buy rating on the shares. The firm adjusted the company's model post the Q4 report.
B. Riley
NULL -> Buy
initiated
$20
2025-08-26
Reason
B. Riley
Price Target
$20
2025-08-26
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Actuate Therapeutics with a Buy rating and $20 price target. The firm views the company's lead asset elraglusib as a "transformative" advancement in pancreatic ductal adenocarcinoma treatment. In a Phase 2 study, elraglusib delivered an "unprecedented" survival benefit in the front-line setting with a 37% reduction in death risk that remained consistent in more aggressive disease characterized by the presence of liver metastasis, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ACTU
Unlock Now

People Also Watch